Monthly cost of three exchanges a day peritoneal dialysis is same as of thrice a week hemodialysis in self-paying Indian patients

Jeloka, Tarun; Upase, S; Chitikeshi, Sanjeevi

doi:10.4103/0971-4065.83739

Cited by 30 publications

(18 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29,852 (USD 609) and 28,763 (USD 585), respectively. 13 Patients often cut down on dialysis frequency for economic reasons. Frequent and often longterm hospitalizations add to the financial burden.…”

Section: Financial and Reimbursement Issuesmentioning

confidence: 99%

“…The two factors that were perceived to militate against PD were cost and high infection rates. Jeloka et al 13 have shown that the costs of the commonly prescribed HD and PD prescriptions are comparable. Fears of infection due to the hot, humid climate and poor hygienic conditions have also turned out to be unfounded; infection rates in most Indian PD programs are acceptable by International standards.…”

Section: Renal Replacement Therapymentioning

confidence: 99%

See 1 more Smart Citation

Current status of end-stage renal disease care in India and Pakistan

Jha

2013

Kidney International Supplements

181

174

View full text Add to dashboard Cite

Section: Financial and Reimbursement Issuesmentioning

confidence: 99%

Section: Renal Replacement Therapymentioning

confidence: 99%

Current status of end-stage renal disease care in India and Pakistan

Jha

2013

Kidney International Supplements

181

174

View full text Add to dashboard Cite

“…In some parts of South India, government-run health insurance schemes pay for dialysis provided in private hospitals [11,12]. …”

Section: Hemodialysismentioning

confidence: 99%

Present Status of Renal Replacement Therapy in Asian Countries

Navva¹,

Sreepada²,

Nayak³

2015

Blood Purif

View full text Add to dashboard Cite

Background: Asia is a huge and populous continent with diverse economies where the status of renal replacement therapy varies among different countries. Summary: The penetration of dialysis is poor among low income countries like India and China. A lack of trained nephrologists and limited numbers of dialysis facilities plague South Asian countries. Most of the hemodialysis centers are in the private sector; the few centers that are government-run or run by charitable organizations cannot meet growing needs. China has shown that twice-a-week hemodialysis can be feasible in female patients with small build. Peritoneal dialysis (PD) has less penetration among the developing countries than the developed countries in Asia. Novel schemes in India including the ‘once-in-a-lifetime payment' scheme and an insurance scheme for peritonitis are attracting more patients to PD. New biocompatible PD solutions and home care facilities have brought down the peritonitis rates. The PD-first policy in Thailand alongside the domestic manufacture of PD fluids has decreased the cost of PD there. Iran has shown drastic changes in its PD policy (from 0 to 1,150 recruitments in 5 years) in spite of its high transplantation rate. Home hemodialysis is practiced in mostly affluent countries like Japan, where again it accounts for only 0.1% of all hemodialysis. Key Messages: Developing countries should have more budgetary allocation for chronic ailments such as chronic kidney disease that can be utilized for training programs and establishing dialysis units, and thus meet the growing demands for renal replacement therapy. PD should be encouraged and adopted as first modality of renal replacement therapy considering its ease and economy.

show abstract

“…The monthly cost of the common dialysis prescriptions, two hemodialysis sessions/week and three peritoneal dialysis exchanges/day, was estimated at 29,852 rupees ($609) and 28,763 rupees ($585), respectively. 5 This statistic clearly shows that despite economic growth there remains a large gap in the proportion of the population who have the means for additional expenditures beyond what is needed for daily living. However, among the proportion of people with access to dialysis, their prognosis and outcomes are similar to most worldwide statistics.…”

Section: The Economic and Cultural Challenges Of Managing Chronic Kidmentioning

confidence: 99%

Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective

Reddy

Sundaram²,

Abraham³

et al. 2014

IJNRD

View full text Add to dashboard Cite

There has been an exponential increase in the incidence of diabetes and hypertension in India in the last few decades, with a proportional increase in chronic kidney disease (CKD). Preventive health care and maintenance of asymptomatic chronic disease such as CKD are often neglected by patients until they become symptomatic with fluid retention and uremia. Management of hyperphosphatemia in CKD remains one of the challenges of nephrology in India for this reason, as it is almost completely asymptomatic but contributes to renal osteodystrophy, metastatic vascular calcification, and acceleration of cardiovascular disease. Lack of understanding of the dangers of asymptomatic hyperphosphatemia, the huge pill burden of phosphate binders, difficulty with dietary and dialysis compliance, and most importantly, the added expense of the drugs places additional road blocks in the treatment of hyperphosphatemia at a population level in developing countries like India. In this review we seek to address the contribution of hyperphosphatemia to adverse outcomes and discuss economic, cultural, and societal factors unique to the management of phosphate levels in Indian patients with advanced CKD.

show abstract

Monthly cost of three exchanges a day peritoneal dialysis is same as of thrice a week hemodialysis in self-paying Indian patients

Cited by 30 publications

References 8 publications

Current status of end-stage renal disease care in India and Pakistan

Current status of end-stage renal disease care in India and Pakistan

Present Status of Renal Replacement Therapy in Asian Countries

Optimal management of hyperphosphatemia in end-stage renal disease: an Indian perspective

Contact Info

Product

Resources

About